BioMarin
BMRN
Performance
About BioMarin
BioMarin is a global biotechnology company that develops medicines to treat rare genetic conditions and lysosomal storage diseases. The company focuses on therapies for conditions such as achondroplasia and severe hemophilia A, with a broad portfolio of eight marketed products and an advancing pipeline across research and development, manufacturing, and clinical trials. Since its founding in 1997, BioMarin has established a worldwide presence and ongoing patient support programs, with operations and information accessible to patients and healthcare professionals globally.
Recent News
5 FDA Decisions to Watch in the First Quarter of 2026
First-Movers Respond to Herding; BioMarin Vets Start New Biotech; GSK Buys RAPT Therapeutics; and More
Ascendis Retreats to Rare Endocrinology Wheelhouse as Cancer Plans Falter
BioCentury’s 2025-26 Picks and Predictions. Plus: BioMarin and More Biotech ICYMI — a BioCentury Podcast
BioMarin’s Mixed Bag of Phase 3 Data Dim Prospects for Rare Disease Drug
BioMarin Notches Win in Study that Could Expand Use of Top-Selling Medicine
Korea’s Ildong Promotes Chae Joon Lee to Co-CEO
BioMarin Vets Spearhead New Biotech with $82M for Rare Disease Drugs
Federal Circuit Review | March 2026
CIBRA Capital Places $21 Million Merger‑Arbitrage Bet on Amicus Therapeutics Ahead of BioMarin Deal
11 Companies Hiring Manufacturing Professionals Now
FDA Grants Full Approval to Travere’s FILSPARI for FSGS, Unlocking $2B Market
Innovative Insights: Legal Updates in the Life Sciences
Novo Nordisk, BioMarin Make AI Moves; Bristol Myers Welcomes Neurology Exec From Eisai
Game Over- No Self-Help Clock Reset for Mandatory Stay Request
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
BioMarin’s ENERGY 3 Trial of BMN 401 Meets One Co-Primary Endpoint
Yuviwel Gets FDA Greenlight as First Once‑Weekly Treatment for Dwarfism in Children
Bone Disease Readout Sinks Mereo, Ultragenyx Shares: Clinical Roundup
Vosoritide Meets Primary Endpoint in Phase 3 Hypochondroplasia Trial, Prompting Planned sNDA Submission to FDA
BioMarin's Voxzogo Shows Surprising Growth Boost in Hypochondroplasia Trial
EU Approves Pfizer’s HYMPAVZI Gene Therapy for Hemophilia A/B with Inhibitors
Moderna Licenses Phase 3 Asset to Recordati; ProMIS' Private Placement
Gene Therapy’s Evidence Problem—Lessons From Recent FDA Decisions
Federal Circuit Patent Watch: Omission of a Coinventor Renders a Patent Invalid When That Error Cannot Be Corrected
Seeking ‘Continuous’ Run of Deals, BioMarin Adds Fabry, Pompe Drugs via $4.8B Amicus Takeout
BioMarin Shows Long‑Term VOXZOGO Gains in Height, Arm Span and Bone Health
The Top 12 Companies Hiring in Biopharma Now
Scaling RNA Therapeutics Sustainably Using the ECO Synthesis Manufacturing Platform
Recent Deals
No recent deals for this company.